恒河猴接种减毒活HSV-1疫苗VC2可刺激黏膜T细胞增殖和生发中心反应并产生持续高水平中和抗体
研究评估减毒活HSV-1疫苗株VC2在恒河猴中的免疫原性。接种动物无疾病迹象,两次加强免疫后HSV-1和HSV-2反应性IgG1升高,IgG2和IgG3维持在低至检测不到水平;所有接种动物产生高水平交叉保护中和抗体。流式细胞术显示引流淋巴结浆母细胞和成熟记忆B细胞显著增加,滤泡辅助T细胞和调节性CXCR5+CD8+细胞毒性T细胞增殖显著增加,血浆CXCL13显著升高提示生发中心活性增强,阴道活检CD4+和CD8+T细胞增殖增加。
要点
- 恒河猴接种VC2后无疾病迹象,两次加强免疫后HSV-1和HSV-2反应性IgG1升高。
- 所有接种动物产生高水平交叉保护中和抗体,IgG1应答持续超过250天。
- VC2接种刺激引流淋巴结浆母细胞、成熟记忆B细胞、滤泡辅助T细胞和调节性CXCR5+CD8+细胞毒性T细胞增殖。
核心结论
- 肌内接种减毒活HSV-1 VC2疫苗株可刺激恒河猴产生持续超过250天的强效IgG1抗体应答,并促进B细胞成熟为浆母细胞和成熟记忆B细胞、滤泡辅助T细胞扩增及黏膜免疫应答影响。
- 作者认为VC2疫苗诱导的强效免疫应答有助于定义保护相关性,从而为开发有效的HSV-1/HSV-2人用疫苗提供依据。
研究设计与样本
- 研究为恒河猴接种减毒活HSV-1 VC2疫苗株的免疫原性实验,VC2株在糖蛋白K(gK)和膜蛋白UL20上带有突变。
- 原文未报告接种动物数量、分组、接种剂量、接种途径的具体方案及随访时长(除提及疫苗接种后超过250天)。
主要发现
- 接种动物无疾病迹象,两次加强免疫后HSV-1和HSV-2反应性IgG1升高,而IgG2和IgG3维持在低至检测不到水平。
- 所有接种动物产生高水平交叉保护中和抗体。
- 引流淋巴结细胞流式分析显示VC2接种刺激浆母细胞(CD27highCD38high)和成熟记忆(CD21-IgM-)B细胞显著增加。
- 引流淋巴结活检T细胞分析显示增殖性(Ki67+)滤泡辅助T细胞和调节性CXCR5+CD8+细胞毒性T细胞统计学显著增加。
- 疫苗接种后两周血浆CXCL13显著升高提示生发中心活性增强;研究期间阴道活检样本中增殖性(Ki67+)CD4+和CD8+T细胞群体呈接种依赖性的增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have shown that the live-attenuated HSV-1 VC2 vaccine strain with mutations in glycoprotein K (gK) and the membrane protein UL20 is unable to establish latency in vaccinated animals and produces a robust immune response capable of completely protecting mice against lethal vaginal HSV-1 or HSV-2 infections. To better understand the immune response generated by vaccination with VC2, we tested its ability to elicit immune responses in rhesus macaques. Vaccinated animals showed no signs of disease and developed increasing HSV-1 and HSV-2 reactive IgG1 after two booster vaccinations, while IgG subtypes IgG2 and IgG3 remained at low to undetectable levels. All vaccinated animals produced high levels of cross protective neutralizing antibodies. Flow cytometry analysis of cells isolated from draining lymph nodes showed that VC2 vaccination stimulated significant increases in plasmablast (CD27highCD38high) and mature memory (CD21-IgM-) B cells. T cell analysis on cells isolated from draining lymph node biopsies demonstrated a statistically significant increase in proliferating (Ki67+) follicular T helper cells and regulatory CXCR5+ CD8+ cytotoxic T cells. Analysis of plasma isolated two weeks post vaccination showed significant increases in circulating CXCL13 indicating increased germinal center activity. Cells isolated from vaginal biopsy samples collected over the course of the study exhibited vaccination-dependent increases in proliferating (Ki67+) CD4+ and CD8+ T cell populations. These results suggest that intramuscular vaccination with the live-attenuated HSV-1 VC2 vaccine strain can stimulate robust IgG1 antibody responses that persist for >250days post vaccination. In addition, vaccination lead to the maturation of B cells into plasmablast and mature memory B cells, the expansion of follicular T helper cells, and affects in the mucosal immune responses. These data suggest that the HSV VC2 vaccine induces potent immune responses that could help define correlates of protection towards developing an efficacious HSV-1/HSV-2 vaccine in humans.
引用
- Stanfield BA, Pahar B, Chouljenko VN, et al. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. Vaccine. 2016. PMID: 28017425. doi:10.1016/j.vaccine.2016.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。